Results 1 to 10 of about 4,751,108 (302)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Journal of Blood Medicine, 2017
Kenneth Lieuw1,2 1Department of Pediatrics, Walter Reed National Military Medical Center, 2Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Abstract: Hemophilia A (HA) is a common bleeding disorder caused ...
Lieuw K
doaj   +1 more source

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulants (DOACs) interfere with clot-based assays, including factor (F)VIII testing and the Nijmegen–Bethesda assay, potentially leading to false-positive results for FVIII inhibitors.
Rick Timmerije, Saskia E.M. Schols, Daniëlle Meijer, Wideke Barteling, An K. Stroobants, Sanna R. Rijpma   +5 more
doaj   +2 more sources

Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies

Medicina, 2023
Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a sudden and unexpected bleeding episode in a patient with no personal or family history of bleeding diathesis, and with a typical laboratory feature, i.e., a ...
Renato Marino
doaj   +1 more source

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Research and Practice in Thrombosis and Haemostasis, 2022
Background Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti ...
Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L. Meeks, Jean‐Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L. Turecek, Nikola Tripkovic, Yesim Dargaud   +9 more
doaj   +1 more source

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A. [PDF]

, 2012
nefficient intracellular protein trafficking is a critical issue in the pathogenesis of a variety of diseases and in recombinant protein production.
Tonn, Torsten, Milanov, Peter, Schüttrumpf, Jörg, Seifried, Erhard, Patricia Quade-Lyssy, Quade-Lyssy, Patricia, Jörg Schüttrumpf, Roth, Stefanie D., Simpson, Jeremy C., Christopher Ungerer, Erhard Seifried, Abriss, Daniela, Pepperkok, Rainer, Rainer Pepperkok, Stefanie D Roth, Jeremy C Simpson, Torsten Tonn, Ungerer, Christopher, Peter Milanov, Daniela Abriss   +19 more
core   +1 more source

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy

Frontiers in Immunology, 2020
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein.
Alex C. Chen, Xiaohe Cai, Chong Li, Liliane Khoryati, Marc A. Gavin, Carol H. Miao   +5 more
doaj   +1 more source

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia

Pilot and Feasibility Studies, 2018
Background The interest of health care agencies, private payers and policy makers for patient-reported outcomes (PRO) is continuously increasing. There is a substantial need to improve capacity to collect and interpret relevant PRO data to support ...
MW. Skinner, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, D. Noone, B. O’Mahony, D. Page, J. S. Stonebraker, A. Iorio   +9 more
doaj   +1 more source

Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]

, 2000
Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N., Gesierich, Wolfgang, Pohlmann, H., Munker, Reinhold, Geiersberger, U., Hartenstein, R.   +5 more
core   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

Haematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat, Jules Russick, Bagirath Gangadharan, Julie Rayes, Mathieu Ing, Jan Voorberg, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +7 more
doaj   +1 more source

Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia a patients with factor VIII inhibitor [PDF]

, 2000
2000-05Eleven Japanese hemophilia A patients with anti-factor VIII (FVIII)a) inhibitors were studied to localize both their inhibitory antibody epitopes and their genotypes.
Kamiya, Tadashi, Matsushita, Tadashi, Yamamoto, Koji, Saito, Hidehiko, Sugihara, Takuro, Okamoto, Yoshihiro, Takahashi, Isao, Kojima, Tetsuhito   +7 more
core   +1 more source